We report a high incidence of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) in patients entered into the Medical Research Council Chronic Lymphocytic Leukaemia-5 trial. Of 115 newly diagnosed patients treated with fludarabine, 65 patients proceeded to autologous transplant. Conditioning was cyclophosphamide and total body irradiation in 49 (75%) patients and chemotherapy in 12 (18%). Ten patients have developed MDS/AML; eight had undergone an autograft. Five-year actuarial risk of developing MDS/AML postautograft was 12·4% (95% confidence interval, 2·5-24%). No analysed potential risk factor was predictive for MDS/AML development. We hypothesise that potential causative factors are fludarabine, low cell dose and transplant conditioning. © 2006 Blackwell Publishing Ltd.
CITATION STYLE
Milligan, D. W., Kochethu, G., Dearden, C., Matutes, E., MacConkey, C., & Catovsky, D. (2006). High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. British Journal of Haematology, 133(2), 173–175. https://doi.org/10.1111/j.1365-2141.2006.05982.x
Mendeley helps you to discover research relevant for your work.